Free Trial

Scholar Rock (SRRK) Competitors

Scholar Rock logo
$32.40 +0.50 (+1.57%)
Closing price 04:00 PM Eastern
Extended Trading
$32.39 -0.01 (-0.03%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SRRK vs. ASND, VTRS, RDY, MRNA, ROIV, QGEN, ELAN, BBIO, VRNA, and RVMD

Should you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

Scholar Rock vs. Its Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Scholar Rock has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$393.54M32.47-$409.12M-$5.16-40.14
Scholar Rock$33.19M93.84-$246.29M-$2.91-11.13

Scholar Rock has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Ascendis Pharma A/S-54.94% N/A -24.31%
Scholar Rock N/A -127.11%-90.09%

91.1% of Scholar Rock shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ascendis Pharma A/S has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

In the previous week, Scholar Rock had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 21 mentions for Scholar Rock and 13 mentions for Ascendis Pharma A/S. Scholar Rock's average media sentiment score of 0.82 beat Ascendis Pharma A/S's score of 0.65 indicating that Scholar Rock is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascendis Pharma A/S
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Scholar Rock
6 Very Positive mention(s)
5 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ascendis Pharma A/S presently has a consensus price target of $248.29, indicating a potential upside of 19.88%. Scholar Rock has a consensus price target of $48.60, indicating a potential upside of 50.00%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts clearly believe Scholar Rock is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascendis Pharma A/S
1 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.88
Scholar Rock
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
3.07

Summary

Scholar Rock beats Ascendis Pharma A/S on 12 of the 17 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRRK vs. The Competition

MetricScholar RockMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.11B$3.40B$6.05B$10.51B
Dividend YieldN/A2.30%5.73%4.80%
P/E Ratio-11.1322.9285.4427.36
Price / Sales93.84268.92516.11196.40
Price / CashN/A46.9537.5761.53
Price / Book8.2210.5512.426.82
Net Income-$246.29M-$52.58M$3.32B$276.89M
7 Day Performance-16.26%1.09%1.01%0.27%
1 Month Performance-3.77%16.09%10.75%8.31%
1 Year Performance13.52%18.41%76.19%35.60%

Scholar Rock Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRRK
Scholar Rock
4.6845 of 5 stars
$32.40
+1.6%
$48.60
+50.0%
+11.9%$3.11B$33.19M-11.13140Options Volume
High Trading Volume
ASND
Ascendis Pharma A/S
3.1962 of 5 stars
$210.83
+3.3%
$244.36
+15.9%
+62.5%$12.59B$393.54M-40.861,017News Coverage
Analyst Forecast
Analyst Revision
High Trading Volume
VTRS
Viatris
2.3836 of 5 stars
$10.13
-0.6%
$10.40
+2.7%
-12.8%$11.88B$14.74B-3.4932,000News Coverage
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7137 of 5 stars
$14.12
-0.3%
$16.95
+20.0%
-11.6%$11.82B$3.81B21.3927,811News Coverage
Positive News
MRNA
Moderna
4.26 of 5 stars
$27.54
-3.3%
$41.81
+51.8%
-54.5%$11.08B$3.24B-3.665,800
ROIV
Roivant Sciences
3.063 of 5 stars
$16.26
+0.6%
$19.94
+22.6%
+38.5%$11.04B$29.05M-23.23860Insider Trade
QGEN
QIAGEN
4.3804 of 5 stars
$46.99
+0.4%
$49.40
+5.1%
+10.8%$10.40B$1.98B27.765,765
ELAN
Elanco Animal Health
2.78 of 5 stars
$20.68
+0.2%
$18.33
-11.3%
+41.0%$10.25B$4.44B24.059,000Analyst Revision
BBIO
BridgeBio Pharma
4.1045 of 5 stars
$54.61
+3.3%
$63.94
+17.1%
+119.2%$10.11B$221.90M-13.35400
VRNA
Verona Pharma PLC American Depositary Share
1.4594 of 5 stars
$106.91
+0.1%
$109.00
+2.0%
N/A$9.20B$42.28M-107.9930Positive News
RVMD
Revolution Medicines
4.1135 of 5 stars
$46.58
-0.3%
$74.64
+60.2%
-3.5%$8.73B$11.58M-10.35250

Related Companies and Tools


This page (NASDAQ:SRRK) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners